GOVERNMENT FUNDING
BioCryst Awarded $102.6M for Flu ResearchBioCryst Pharmaceuticals Inc., Birmingham, Ala., has been awarded a $102.6 million, four-year contract from the US Department of Health and Human Services to develop the influenza neuraminidase inhibitor, peramivir, to treat seasonal and life-threatening influenza, including avian flu.
Full ArticleGlaxoSmithKline Receives $63M for Pandemic Vaccine ResearchGlaxoSmithKline (GSK), Brentford, UK, was awarded a contract from the US Department of Health and Human Services to develop pre-pandemic and pandemic flu vaccines and supports GSK’s ongoing pandemic vaccine research using adjuvant technology in combination with antigens to induce a strong immune response.
Full ArticleNovartis Awarded $55M Contract for Antigen TechnologyNovartis, Basel, Switzerland, has received a contract from the US Department of Health and Human Services for approximately $55 million to support its efforts to bring the antigen-sparing capabilities of the MF59 adjuvant to the United States for influenza vaccine research.
Full ArticleUniversity of Pittsburgh Awarded $13M for COPD ResearchThe University of Pittsburgh has been awarded an estimated $13 million for a five-year research grant from the National Heart, Lung and Blood Institute to develop novel approaches to increase the understanding of, and improve outcomes for, people with chronic obstructive pulmonary disease (COPD).
Full ArticlePRIVATE FUNDING
Cylene Pharmaceuticals Closes $44M in Series C FinancingCylene Pharmaceuticals Inc., San Diego, Calif., a small molecule oncology drug discovery and development company, announced the closing of a $44 million Series C financing, that will be used to fund human clinical trials for phase II studies of CX-3543 in several different cancer indications and to advance two more products into development.
Full ArticleCalypso Pockets $42.2M Financing for ExpansionCalypso Medical Technologies Inc., Seattle, announced that it has closed its Series D private equity financing totaling $42.2 million to support the market launch of the company’s 4D Localization System for use in patients undergoing radiation treatment for prostate cancer.
Full ArticleVariation Biotechnologies Secures $35.7M in Series A FinancingVariation Biotechnologies Inc., Gatineau, Canada, a privately held biopharmaceutical company focused on the development of vaccines for infectious diseases using a novel platform technology, has secured $35.7 million in Series A financing.
Full ArticleInteKrin Secures $23M in Venture FinancingInteKrin Therapeutics Inc., Palo Alto, Calif., a clinical stage biopharmaceutical company focused developing products for diabetes, metabolism, and obesity, has secured $23 million in venture financing.
Full ArticleSequoia Raises $22M in Series C FinancingSequoia Pharmaceuticals Inc., Gaithersburg, Md., has raised $22 million in a Series C financing that will be used to further develop its pipeline candidates to treat drug-resistant HIV infections, including an HIV protease inhibitor and a pharmacokinetic enhancer.
Full ArticleGRANTS AVAILABLE
Innovative Technologies for Molecular Analysis of CancerAgency: National Cancer Institute
Estimated Funding: $200,000
Due Date for Applications: Multiple dates, see Web site
Description: This grant solicits research projects focused on the development of highly innovative cancer-relevant molecular biology technologies, including instrumentation, techniques, and devices.
Full ArticleInnovations in Cancer Sample PreparationAgency: National Institutes of Health
Estimated Funding: $200,000
Due Date for Applications: Multiple dates, see Web site
Description: This grant solicits research projects to develop and significantly enhance or adapt sample preparation methodologies and technologies, the development of assays to assess sample quality, and studies designed to elucidate the criteria by which to judge sample quality.
Full Article Shared Neurobiology of Fragile X Syndrome and AutismAgency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This funding opportunity is aimed at characterizing, understanding, and treating etiological and pathophysiological mechanisms common to both Fragile X syndrome and autism (including autism spectrum disorders such as Rett syndrome).
Full Article Epigenetic Approaches in Cancer EpidemiologyAgency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This grant seeks to stimulate population-based epidemiology research on the roles of DNA methylation markers in cancer. The size and duration of each award will vary.
Full Article Insulin Signaling and Receptor Cross-TalkAgency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This grant seeks applications to investigate crosstalk in insulin responses at molecular, cellular, and physiological levels to broaden our understanding of how insulin signals act to regulate coordinated responses between and among insulin responsive tissues.
Full Article Neurobiology of MigraineAgency: National Institute of Neurological Disorders and Stroke
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This program announcement solicits grant applications from institutions/organizations that intend to perform innovative research to expand current knowledge of neurobiological mechanisms underlying the phases of migraine and the role of neuromodulators such as sex hormones, and genetic influences in migraine pathophysiology.
Full Article Novel Approaches to Enhance Animal Stem Cell ResearchAgency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This grant encourages applications for research to enhance animal stem cells as model biological systems. Innovative approaches to isolate, characterize, and identify toti-potent and multi-potent stem cells from nonhuman biomedical research animal models, as well as to generate reagents and techniques to characterize and separate those stem cells from other cell types, is encouraged.
Full Article